John Griffin is responsible for Numerate's therapeutic programs and collaborations. He was formerly co-founder and Chief Scientific Officer of Theravance, Inc., a publicly traded biopharmaceutical company. A former Assistant Professor at Stanford University, John is also the author of 39 scientific publications, an inventor of 27 issued patents, and the recipient of numerous awards including an Arthur C. Cope Scholar Award from the American Chemical Society and a Dean's Award for Teaching from Stanford University. He has also served on the Funding Committee for the Wellcome Trust's Seeding Drug Discovery Initiative. John received a B.S. in Chemistry from Hope College, a Ph.D. in Chemistry from the California Institute of Technology and was a National Science Foundation Postdoctoral Fellow at Harvard Medical School.